

# Roger K Cady

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9135448/publications.pdf>

Version: 2024-02-01

60  
papers

3,874  
citations

136950

32  
h-index

138484

58  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of Calcitonin Gene-Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy. <i>Headache</i> , 2004, 44, 35-43.	3.9	479
2	Treatment of Acute Migraine With Subcutaneous Sumatriptan. <i>JAMA - Journal of the American Medical Association</i> , 1991, 265, 2831.	7.4	248
3	Efficacy and safety of eptinezumab in patients with chronic migraine. <i>Neurology</i> , 2020, 94, e1365-e1377.	1.1	236
4	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. <i>Neurology</i> , 2015, 84, 688-695.	1.1	219
5	Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. <i>Clinical Therapeutics</i> , 2000, 22, 1035-1048.	2.5	217
6	Sumatriptan for the Range of Headaches in Migraine Sufferers: Results of the Spectrum Study. <i>Headache</i> , 2000, 40, 783-791.	3.9	215
7	Sumatriptan for the Range of Headaches in Migraine Sufferers: Results of the Spectrum Study. <i>Headache</i> , 2000, 40, 783-791.	3.9	207
8	Salivary Levels of CGRP and VIP in Rhinosinusitis and Migraine Patients. <i>Headache</i> , 2006, 46, 24-33.	3.9	135
9	Sinus headache or migraine?. <i>Neurology</i> , 2002, 58, S10-4.	1.1	124
10	Primary Headaches: A Convergence Hypothesis. <i>Headache</i> , 2002, 42, 204-216.	3.9	107
11	Elevated Saliva Calcitonin Gene-Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan. <i>Headache</i> , 2009, 49, 1258-1266.	3.9	99
12	Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 908-916.	3.0	97
13	A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With $\text{360}^{\circ}$ as Acute Treatment for Chronic Migraine. <i>Headache</i> , 2015, 55, 101-116.	3.9	87
14	Treating Early Versus Treating Mild: Timing of Migraine Prescription Medications Among Patients With Diagnosed Migraine. <i>Headache</i> , 2005, 45, 538-545.	3.9	76
15	Sinus headache: a clinical conundrum. <i>Otolaryngologic Clinics of North America</i> , 2004, 37, 267-288.	1.1	74
16	Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. <i>Current Medical Research and Opinion</i> , 2004, 20, 1465-1472.	1.9	70
17	Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack. <i>Headache</i> , 2006, 46, 914-924.	3.9	67
18	Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine. <i>Headache</i> , 2011, 51, 1573-1577.	3.9	67

#	ARTICLE	IF	CITATIONS
19	Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERTI; 1/2 Early Migraine Intervention) Tj ETQq1 1 0,784314 rgBT /Ove	3.9	64
20	A Pilot Study to Measure Cognitive Efficiency During Migraine. Headache, 2000, 40, 657-661.	3.9	62
21	Understanding the Patient With Migraine: The Evolution From Episodic Headache to Chronic Neurologic Disease. A Proposed Classification of Patients With Headache. Headache, 2004, 44, 426-435.	3.9	61
22	A Double-blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic <sup>TM</sup> ) in the Treatment of Migraine. Headache, 2011, 51, 1078-1086.	3.9	61
23	Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia, 2011, 31, 18-30.	3.9	53
24	Botulinum Toxin Type A as Migraine Preventive Treatment in Patients Previously Failing Oral Prophylactic Treatment Due To Compliance Issues. Headache, 2008, 48, 900-913.	3.9	50
25	A Randomized, Double-blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (<sc>AVP</sc> 825) in the Treatment of Acute Migraine (The <sc>TARGET</sc>) Tj ETQq1 1 0,784314 rgBT	3.9	44
26	Long-Term Efficacy of a Double-blind, Placebo-Controlled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the <sc>Tx</sc>360<sup>A</sup> Device for Treatment of Chronic Migraine. Headache, 2015, 55, 529-542.	3.9	44
27	<sc>AVP</sc> 825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The <sc>COMPASS</sc> Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache, 2015, 55, 621-635.	3.9	44
28	Needle-Free Subcutaneous Sumatriptan (Sumavel, DosePro): Bioequivalence and Ease of Use. Headache, 2009, 49, 1435-1444.	3.9	43
29	The Bowel and Migraine: Update on Celiac Disease and Irritable Bowel Syndrome. Current Pain and Headache Reports, 2012, 16, 278-286.	2.9	43
30	An Exploratory Study of Salivary Calcitonin Gene-Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With Onabotulinumtoxin A in Chronic Migraine. Headache, 2014, 54, 269-277.	3.9	40
31	Changes in Salivary Prostaglandin Levels During Menstrual Migraine With Associated Dysmenorrhea. Headache, 2010, 50, 844-851.	3.9	39
32	Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Current Pain and Headache Reports, 2005, 9, 47-52.	2.9	34
33	Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Double-blind Trial. Headache, 2009, 49, 216-226.	3.9	32
34	Predictors of Adherence to Triptans: Factors of Sustained vs Lapsed Users. Headache, 2009, 49, 386-394.	3.9	31
35	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. Mayo Clinic Proceedings, 2007, 82, 61-68.	3.0	25
36	Sinus problems as a cause of headache refractoriness and migraine chronification. Current Pain and Headache Reports, 2009, 13, 319-325.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. Mayo Clinic Proceedings, 2007, 82, 61-68.	3.0	20
38	Satisfaction With and Confidence in Needle-Free Subcutaneous Sumatriptan in Patients Currently Treated with Triptans. Headache, 2011, 51, 1202-1211.	3.9	20
39	A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. Expert Opinion on Drug Delivery, 2015, 12, 1565-1577.	5.0	20
40	Total Migraine Freedom, a Potential Primary Endpoint to Assess Acute Treatment in Migraine: Comparison to the Current FDA Requirement Using the Complete Rizatriptan Study Database. Headache, 2011, 51, 356-368.	3.9	17
41	Treatment of Chronic Migraine: A 3-Month Comparator Study of Naproxen Sodium vs Sumatriptan. Headache, 2014, 54, 80-93.	3.9	17
42	Does Early Migraine Treatment Shorten Time to Headache Peak and Reduce Its Severity?. Headache, 2008, 48, 914-920.	3.9	15
43	Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications. Headache, 2012, 52, 749-764.	3.9	15
44	Acupuncture in the Treatment of Headache: A Traditional Explanation of an Ancient Art. Headache, 2015, 55, 457-464.	3.9	13
45	Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Current Medical Research and Opinion, 2011, 27, 2185-2191.	1.9	12
46	Sumatriptan vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study. Headache, 2014, 54, 67-79.	3.9	12
47	Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination. Current Medical Research and Opinion, 2009, 25, 2711-2721.	1.9	11
48	Red Flags and Comfort Signs for Ominous Secondary Headaches. Otolaryngologic Clinics of North America, 2014, 47, 289-299.	1.1	11
49	Predictability of Future Attacks by Migraineurs: A Prospective Observational Study. Headache, 2010, 50, 1296-1305.	3.9	10
50	Advances in Drug Development for Acute Migraine. Drugs, 2012, 72, 2187-2205.	10.9	10
51	OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opinion on Biological Therapy, 2010, 10, 289-298.	3.1	9
52	The Development of a Survey to Measure Completeness of Response to Migraine Therapy. Headache, 2012, 52, 550-572.	3.9	9
53	The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine. Expert Opinion on Pharmacotherapy, 2015, 16, 2039-2051.	1.8	6
54	Managing migraine by patient profile: role of frovatriptan. Patient Preference and Adherence, 2016, 10, 501.	1.8	6

#	ARTICLE	IF	CITATIONS
55	The Future of Migraine: Beyond Just Another Pill. Mayo Clinic Proceedings, 2009, 84, 397-399.	3.0	5
56	Multi-Center Comparison of Response to a Single Tablet of Sumatriptan 85µmg and Naproxen 500µmg vs Usual Therapy Treating Multiple Migraine Attacks as Measured by the Completeness of Response Survey. Headache, 2011, 51, 961-970.	3.9	4
57	The epidemiology and pathophysiology of migraine. Managed Care, 2007, 16, 4-9; discussion 15-7.	0.3	4
58	Acute and Preventative Treatment of Episodic Migraine. , 2015, , 69-97.		1
59	Chronic Migraine. , 2015, , 99-122.		1
60	Ophthalmic beta blockers: treatment for acute migraine?. Missouri Medicine, 2014, 111, 292-3.	0.3	1